Validex
A quality workspace that inventories regulated spreadsheets, captures intended use and process risk, proposes a risk-based assurance plan, preserves executed evidence and deviations, and assembles reviewer-approved records with correction and lifecycle control.
The supplied research confirms final FDA computer-software-assurance guidance from September 2025 and says spreadsheets with custom formulas appear in risk-based examples. It also confirms broader validation and quality-system competitors but found no spreadsheet-specific lightweight product. Two of four referenced interfaces remain unverified, no structural incumbent cost is established, and a skipped buildability review must be revisited before implementation.
Validex must not assign regulatory risk or produce a document that is automatically acceptable to FDA. Intended use, process impact, patient or product risk, spreadsheet complexity, controls, data, formulas, macros, interfaces, security, change, reviewer competence, and the manufacturer's quality system determine assurance. Standards and regulations apply by actual product, role, market, and current version.
The tool produces proposals and evidence envelopes. Qualified quality owners approve classification, assurance methods, expected results, deviations, remediation, release, periodic review, retirement, and the final record. A generated record never proves validation, compliance, inspection acceptance, product quality, or patient safety.
Quality and validation teams at medical-device and life-sciences organizations that maintain spreadsheet inventories under a risk-based software assurance program.
Recent final guidance and quality-system transition create current attention.
Quality engineers and validation owners are specific.
Several quality, compliance, and evidence neighbors support the workflow.
The quality buyer, final guidance, spreadsheet inventory, intended-use risk method, and assurance record are concrete.
Two interfaces and buildability remain unverified, broad incumbents exist, no structural moat is shown, regulatory judgment is high stakes, and organizations have different quality systems.
Discussion
No comments yet — be the first to weigh in.